ClinicalTrials.gg
Active, not recruitingNCT04740476Updated Feb 4, 2026

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

A Phase 2 interventional study of zorevunersen (STK-001) in Dravet Syndrome, sponsored by Stoke Therapeutics, Inc. Active, not recruiting at 17 sites in United States. Open to participants aged 30 Months and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Stoke Therapeutics, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
30 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies in Epilepsies, Myoclonic with a site in United States — 11 open to participants now, 17 under way, 4 of them phase 3. Epilepsies, Myoclonic · United States.

Planned enrollment
18th of 43
60 · median 36
Started
2021
with 5 others
Phase 2
9 of 61
1 open now
Primary completion
2029-03
later than 14 of 16 live
Registered
39th of 61
by date
Lead sponsor
3 of 61
Stoke Therapeutics, Inc

Among the 61 studies in Epilepsies, Myoclonic with a site in United States, this one is the 18th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2021, is one of 9 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 39th registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

11 of the 61 studies in Epilepsies, Myoclonic with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 30 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Epilepsies, Myoclonic with a site in United States, or all of them as a file.
02

Study summary

Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

Read the detailed description

This study is a multi-center, open-label, multiple-dose, safety extension study for patients who have completed another study of zorevunersen and meet study eligibility criteria. zorevunersen is an investigational new medicine for the treatment of Dravet syndrome. Zorevunersen is an antisense oligonucleotide (ASO) that is intended to increase the level of productive SCN1A messenger RNA (mRNA) and consequently increase the expression of the sodium channel Nav1.1 protein. This RNA-based approach is not gene therapy, but rather RNA modulation, as it does not manipulate nor insert genetic deoxyribonucleic acid (DNA).

Zorevunersen is designed to upregulate Nav1.1 protein expression from the nonmutant (wild-type) copy of the SCN1A gene to restore physiological Nav1.1 levels. Nav1.1 levels are reduced in people with Dravet syndrome. Stoke has generated preclinical data demonstrating proof-of-mechanism for zorevunersen.

03

Conditions studied

  • Dravet Syndrome

Browse trials for

Keywords

  • Pediatric epilepsy
  • Epileptic Encephalopathies
  • Refractory Myoclonic Epilepsy
  • Severe Myoclonic Epilepsy in Infancy
04

Who can participate

Ages eligible
30 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed dosing with zorevunersen and the End of Study Visit in Study STK-001-DS-101 or Study STK-001-DS-102, with an acceptable safety profile per Investigator judgment.
  • Had satisfactory compliance with study visits and procedures in Study STK-001-DS-101 or Study STK-001-DS-102 per Investigator and Sponsor judgment.
  • Completed Study STK-001-DS-101 or STK-001-DS-102 within 4 weeks of the start of their participation in Study STK-001-DS-501 unless approved by sponsor.

Exclusion criteria

Exclusion Criteria:

  • Met any withdrawal criteria from Study STK-001-DS-101 or STK-001-DS-102.
  • Currently treated with an antiepileptic drug (AED) acting primarily as a sodium channel blocker, as maintenance therapy, including phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide or rufinamide (with the exception of cenobamate, which is permitted).
  • unstable medical conditions other than epilepsy.
  • Clinically relevant symptoms or a clinically significant illness (in the judgment of the Investigator) at Screening or prior to dosing on Day 1, other than epilepsy.
  • Spinal deformity or other condition that may alter the free flow of CSF or has an implanted CSF drainage shunt.
  • Treated (or is being treated) with an product (other than zorevunersen) since participating in Study STK-001-DS-101 or STK-001-DS-102.
  • Participating in an observational study, they are excluded unless approved by the Sponsor.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    zorevunersen (STK-001) multiple dose levels

    Enrollment of patients after completion of Study STK-001-DS-101 or Study STK-001-DS-102 if eligible. Patients will receive IT administration of study drug zorevunersen at the dose level they received while participating in Study STK-001-DS-101 or STK-001-DS-102, or at a dose level recommended by the Safety Monitoring Committee (SMC).The highest dose administered in this study may not exceed that which has already been evaluated in an zorevunersen Phase 1/2 study, and doses above 45 mg/dose in this study require approval from the Food and Drug Administration (FDA). Patients will initially receive 3 doses, one every approximately 4 months (16 weeks). Patients who are tolerating treatment may continue treatment with doses approximately every 4 months, with an End of Study/Follow-up Visit 24 weeks after the last dose of study drug. Patients who do not continue treatment after the third dose will have a Follow-up Visit (V5) at Week 48 and an End of Study Visit at Week 56.

    Drug: zorevunersen (STK-001)

Interventions

  • zorevunersen drug product is an antisense oligonucleotide administered as an intrathecal injection.

06

What researchers measure

Primary outcomes

  1. Safety of multiple doses of zorevunersen

    Safety variables for analysis include the incidence, type, severity, and seriousness of AEs, and changes in vital signs, ECG, laboratory, immunogenicity, physical examination, and outcomes on the cerebellar function clinical screening battery.

    Time frame: Screening (Day -1) until 6 months after multiple drug dosing

Secondary outcomes

  1. Pharmacokinetic (PK) Parameters

    Analysis of plasma concentrations of zorevunersen

    Time frame: Dosing (Day 1) until 6 months after multiple drug dosing

  2. Exposure of zorevunersen in Cerebrospinal Fluid (CSF)

    Measurement of zorevunersen concentrations

    Time frame: Dosing (Day 1) and every 4 months until last study drug dosing day

  3. Measurement of Seizure Frequency

    Measurement of Seizure Frequency (by paper diary)

    Time frame: Screening (Day -1) until 6 months after multiple drug dosing

  4. Change in overall clinical status

    Change in overall clinical status as measured by the Clinical Global Impression of Change (CGIC) and the Caregiver Global Impression of Change (CaGIC)

    Time frame: Screening (Day -1) until 6 months after multiple drug dosing

  5. Change in Quality of Life

    Change in quality of life as measured by the EuroQoL-five dimensions, youth version (EQ-5D-Y) instrument

    Time frame: Screening (Day -1) until 6 months after multiple drug dosing

07

Study locations

17 sites
08

References and documents

Publications

  • Laux L, Sullivan J, Perry MS, Brunklaus A, Desurkar A, Schreiber JM, Roberts CM, Knupp KG, Wheless JW, Wirrell EC, Ventola P, Wang F, Meena, Lynch J, Parkerson KA, Ticho B, Cross JH; MONARCH, ADMIRAL, SWALLOWTAIL, and LONGWING Study Groups. Zorevunersen in Children and Adolescents with Dravet Syndrome. N Engl J Med. 2026 Mar 5;394(10):969-982. doi: 10.1056/NEJMoa2506295. PubMed 41780062 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Mar 2029, 98 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 5, 2021
StartActual
Jan 20, 2021
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04740476
Lead sponsor
Stoke Therapeutics, Inc
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Jan 20, 2021
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Feb 4, 2026

Study contacts

Ann Dandurand, MD
study director · Medical Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zorevunersen

Start the discussion